help_outline Skip to main content


Things looking a little different since your last visit? Don't worry - it's us, not you!

We are currently in the process of updating this website to better improve
your experience, but you should still be able to access all the information as usual. 

Thank you for your patience and we look forward to launching the new design for you!

Shopping Cart
cancel

News / Articles

Effects of Shuanghuanglian Oral Liquids on Patients With COVID-19: A Randomized, Open-Label

Li Ni et al.  | Published on 6/1/2021
We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in addition to standard care. The control group was composed of 59 patients who received standard therapy alone. Treatment with SHL was not associated with a difference from standard care in the time to disease recovery. Read more here.

All News / Articles